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Background: HIV-infection results in damage and dysfunction of the gastrointestinal system. HIV enteropathy
includes pronounced CD4+ T-cell loss, increased intestinal permeability, and microbial translocation that promotes
systemic immune activation, which is implicated in disease progression. A synbiotic is the combination of probiotics
and prebiotics that could improve gut barrier function. Our study goal was to determine whether the use of a
synbiotic, probiotics or a prebiotic can recover immunological parameters in HIV-infected subjects through of a
reduction of microbial translocation and pro-inflammatory cytokine production.
Methods: A randomized, double-blind controlled study was performed; twenty Antiretroviral treatment-naïve
HIV-infected subjects were subgrouped and assigned to receive a synbiotic, probiotics, a prebiotic, or a placebo
throughout 16 weeks.
Results: We had no reports of serious adverse-events. From baseline to week 16, the synbiotic group showed a
reduction in bacterial DNA concentrations in plasma (p = 0.048). Moreover, the probiotic and synbiotic groups
demonstrated a decrease in total bacterial load in feces (p = 0.05). The probiotic group exhibited a significant
increment of beneficial bacteria load (such as Bifidobacterium; p = 0.05) and a decrease in harmful bacteria load
(such as Clostridium; p = 0.063). In the synbiotic group, the CD4+ T-cells count increased (median: +102 cells/μL;
p = 0.05) and the level of Interleukin 6 cytokine decreased significantly (p = 0.016).
Conclusions: Our study showed a significant increase in CD4+ T lymphocyte levels in the synbiotic group, which
could delay the initiation of antiretroviral therapy and decrease costs in countries with limited resources.Introduction
A huge Gastrointestinal (GI) pathology is observed in
patients infected with HIV even during primary infec-
tion. Approximately 60% of total CD4+ T cells, reside
in Gut-associated lymphoid tissue (GALT), and of all
tissues, the latter is one of the most strongly affected
during HIV infection [1]. In 1984, Kotler and collabora-
tors described HIV enteropathy; subsequently, several* Correspondence: jaime.andradev@gmail.com
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distribution, and reproduction in any mediumstudies have demonstrated HIV-associated damage to
the GI tract [2-4].Gastrointestinal damage in HIV infection and microbial
translocation
Once HIV enters the mucosa of the gut, it finds a large
pool of resting Ki67-CD4+ T cells; up to 60% of these
cells are infected and are capable of produce the virus,
constituting a dense network of cells in the intestinal
mucosa, which is capable of spreading the infection to
uninfected cells through cell-to-cell contact. This spread
allows the maintenance of a continuous chain of viral
transmission and forms part of a large reservoir that isoMed Central Ltd. This is an Open Access article distributed under the terms of
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, provided the original work is properly cited.
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activated CD4+ T cells (effector) produce high viral-load
levels, generating high viral gradient in the mucous
membrane tissues, resulting in infection amplification
and spread over long distances [5].
HIV exerts a direct effect on enterocytes. The viral tat
protein inhibits glucose uptake by the enterocytes, alter-
ing their function; the gp120 protein increases enterocyte
intracellular calcium and causes tubulin depolymerization,
in turn causing cytoskeleton dysfunction, with destabili-
zation of intercellular junctions and further increased
intestinal permeability. There is a simultaneous occur-
rence of a decrease in the expression of genes involved
in epithelial mucosal repair (such as trefoils) and
increased immune activation genes, leading to high levels
of pro-inflammatory cytokines as Tumor necrosis factor
(TNF)-α, Interferon (INF)-γ, and Interleukin (IL)-6, -8,
and −12 [2,6].
The enteropathy associated with HIV-infection is char-
acterized by villous atrophy, crypt hyperplasia, vitamin
B12 and bile acid malabsorption, epithelial cell damage,
with enterocyte apoptosis and disruption of tight and
adherent junctions with an increase in intestinal perme-
ability; moreover, depletion of Peyer’ s patches as well as
of CD4+ T cells in lamina propria combined with a
reduced ability to produce secretory IgA and defensins
comprise conditions that favor persistent microbial over-
growth in the intestinal lumen, microbial translocation
with increased plasma levels of Lipopolysaccharides
(LPS), and 16S rRNA, which can provoke the develop-
ment of chronic local and systemic immune stimulation
that may lead to disease progression [2,7-11].Effect of microbiota on the immune system
Microbiota of intestinal tract constitute a complex eco-
system of microorganisms; there are from 10–100 tril-
lion microorganisms that populate the adult intestine
and these provide some benefits to the host [12]. HIV
infection alters gut microbial ecology [13]. Several pro-
biotic organisms and prebiotic agents have shown to
enhance intestinal epithelial barrier functions, reduce
inflammation, and support effective Th-1 responses [14].
Synbiotics are the combination of probiotics plus pre-
biotics. The definition of probiotics is live microbial feed
supplements that confer health benefits when adminis-
tered in adequate amounts (107-1011 colony forming
units (cfu)) and are classified by the US Food and Drug
Administration (FDA) as “live biotherapeutics” when
utilized in humans [15,16]. Probiotics exert an effect
on the immunological response; they mainly stimulates
polymeric IgA secretion, avoid bacterial overgrowth and
their translocation, and produce a self-limited inflam-
matory response through development of regulatory T(Treg) cells by anti-inflammatory cytokine production
[12,15,17-19].
Prebiotics are non-digestible oligosaccharides that
selectively stimulate the growth of some bacteria,
altering the composition and metabolic activity of gut
microbiota [20]. A study in mice demonstrated that
administration of prebiotics such as FructoOligoSac-
charides (FOS) exerts an immunostimulating effect
on inductive sites such as Peyer’s patches [21]. Inulin-
type fructans are non-digestible oligosaccharides with
prebiotic properties and can be obtained from agave
plants [22,23].
The diversity of GI microbiota is directly related with
the number of nutrients [24] and lower beneficial bac-
teria counts in feces have been reported in HIV-infected
subjects compared with healthy controls [13].
Patients with HIV suffer immunological and structural
defects in GI tract; thus, new interventions in HIV-
positive patients are necessary to restore the integrity of
the epithelial and immune system of GALT and block the
ways through which microbial products cause chronic
immune activation. Therefore, we evaluated the use of
a synbiotic, probiotics and a prebiotic to expand bene-
ficial microbiota that aid in decreasing bacterial transloca-
tion and pro-inflammatory cytokine production, thereby
improving immune functions in HIV-infected subjects.Materials and methods
Study design and participants
A randomized, prospective, double-blind controlled pilot
study was conducted in HIV-infected adult patients who
were divided into four groups to receive the following:
group I: probiotics; group II: the synbiotic; group III: the
prebiotic, and group IV: the placebo. The patients were
recruited from August 2008 through June 2009 at the
HIV Unit Department of Hospital Civil de Guadalajara
Fray Antonio Alcalde.
Patients were randomly assigned to receive probiotics,
a synbiotic, a prebiotic, or placebo during 16 weeks; all
products (gel formulation) were made by biotechnology
company called Biotek in Guadalajara city, they required
refrigeration and were taken once daily. We used 10 g of
agavins from Agave tequilana Weber var. azul as the
prebiotic; these types of fructans comprise a complex
mixture of FOS containing mainly β(2–1) linkages, and
some β(2–6) linkages, with branches and a glucose moi-
ety [23]. As probiotics, we employed Lactobacillus
rhamnosus HN001 plus Bifidobacterium lactis Bi-07 at
109 cfu/mL, and the synbiotic was the combination of
probiotics plus prebiotic, the placebo was a product of
Biogel without the two types of probiotics and without
the prebiotic, but with the same flavor and characteris-
tics. The Institutional Review Board at the study site
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diately after providing written informed consent.
Inclusion criteria included the following: documented
HIV infection; age between 18 and 65 years; negative for
Hepatitis B and C viruses; Antiretroviral (ARV) treat-
ment-naïve, in stage A or B according to the U.S. Centers
for Disease Control and Prevention (CDC) classification
system, with a CD4+ count of >350 cells/mm3. Patients
were not included in the study if they were pregnant, had
hepatic or renal insufficiency, cancer, immunotherapy,
use of antibacterial therapy (for >15 days), had know-
ledge of an allergy to bovine milk proteins or if the dose
compliance with the gel formulation was <95%.
Safety parameters and assessment of quality of life (QoL)
assessment
Participating patients were requested to check their body
temperature, to report immediately to the researcher for
possible symptoms of infections, and were examined
by means of laboratory and physical testing at least
once monthly.
The Irritable Bowel Syndrome-Quality of life (IBS-
QoL) questionnaire in a local language was utilized to
evaluate the impact of gastrointestinal symptoms or
treatment complications at baseline and at 16-week vis-
its. The IBS-QoL is a self-administered instrument
employed to derive an overall score with a 34-item,
condition-specific questionnaire that has been approved
for identifying GI-related QoL measures in HIV-infected
patients [25,26], in whom highest scores signify poorest
IBS-related QoL in our study.
Immunological variables determined at baseline and at
week-16 visits
Absolute CD4+ T-lymphocyte count
Absolute CD4+ T-cell counts were quantified as abso-
lute concentration (cells per cubic mm) by means of
flow cytometry at a state-certified laboratory.
Cytokines levels
We measured IL-10 concentrations in plasma as anti-
inflammatory cytokine, and pro-inflammatory cytokines
IL-1β, IL-6, and TNF-α by ELISA using commercially




HIV-1 RNA was measured in plasma at baseline and
at week 16, with the AMPLICOR HIV-1 MONITOR
ultrasensitive assay (Roche Diagnostics, version 1.0)
with a lower detection limit of 50 copies/mL at a state-
certified laboratory.Purification of bacterial DNA in plasma and stool
From 200 μL of plasma and from 200 g of frozen stool
samples, bacterial DNA was extracted employing the
DNeasy Blood and Tissue Kit and QIAamp DNA Stool
Mini Kit (Qiagen), respectively, both according to the
manufacturer’s instructions. DNA concentrations were
determined with a DU 640 spectrophotometer.
Quantitative (q) PCR for bacterial 16S rRNA in plasma
and feces
Bacterial translocation was measured by means of 16S
rRNA levels in plasma, and 16S rRNA levels in feces
were utilized to determinate total bacterial load in stool.
We used a final volume of 10-μL amplification reaction
consisting of 2 μL of 1X PCR buffer (Light Cycler Fast
Start DNA Master Plus Reaction Mix SYBRGreen I,
Roche), 5 pmol forward and 5 pmol reverse primers and
2 ng of template plasma DNA or template feces DNA
(for total bacterial load in feces). We employed the fol-
lowing primer pairs: forward (8 F: 50-AGT TTG ATC
CTG GCT CAG-3) and reverse (515R: 50-GWA TTA
CCG CGG CKG CTG-30) primers to amplify bacterial
DNA templates encoding 16S rRNA [10,27]. We ampli-
fied the DNA in triplicate and calculated mean values.
The count was absolute using a standard curve with the
four dilutions of concentrations known of a standard
plasmid DNA. Conditions for the DNA amplification
reaction comprised 95°C for 10 min, followed by
40 cycles at 95°C for 10 s, 60°C for 10 s, and 72°C for
22 s. Thereafter a melting temperature analysis was
performed as follows: at 95°C for 10 s; at 60°C for 1 min,
and by slowly heating the sample to 95°C at a
temperature rate of 0.1°C/s.
Quantitative PCR (qPCR) for Bifidobacterium and
Clostridium spp. in feces
To detect changes in stool bacterial composition at base-
line and at week 16, we measured the bacterial loads,
dividing as beneficial bacteria the Bifidobacterium spp.
Load, and as harmful bacteria, the Clostridium spp. load.
The primer pairs used to detect Bifidobacterium spp.
were the following: forward 50-CGC GTC YGG TGT
GAA AG-30and reverse 50-CCC CAC ATC CAG CAT
CCA-30 [27,28]. The primer pairs to quantify Clostrid-
ium spp. were forward 50-AAA TGA CGG TAC CTG
ACT AA-30 and reverse 50-CTT TGA GTT TCA TTC
TTG CGA A-30 [27,29]. All qPCR reactions were per-
formed in a final volume of 10 μL consisting of 2 μL
of 1X PCR buffer (Light Cycler Fast Start DNA Master
Plus Reaction Mix SYBRGreen I, Roche), 5 pmol of for-
ward and 5 pmol of reverse primers, and 2 ng of tem-
plate feces DNA. The following amplification conditions
were employed: 95°C for 10 min; followed by 40 cycles
at 95°C for 15 s, at 65°C or 60°C (for Clostridium or
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10 s. Additionally, melting temperature analysis was
performed as follows: at 95°C for 10 s; at 60°C for 1 min,
and by slowly heating the sample to 95°C at a
temperature rate of 0.1°C/s.Statistical analysis
Comparisons among all groups were carried out by per-
forming the Kruskal-Wallis and the Mann–Whitney U
tests. Correlations were analyzed utilizing Spearman
rank-correlation for nonparametric data. Other sta-
tistical tests employed are indicated in the text. All
statistical analysis was undertaken using SPSS version
14 software.Results
Subject characteristics
The study included 20 patients, with five participants for
each of four groups. Characteristics of the patients in
the four groups were similar and are depicted in Table 1.
They did not show malnutrition or wasting syndrome,
and metabolic variables fell within normal ranges at
all times. IBS-QoL scores were similar and did not
worsen during the study in either treatment arm (base-
line data are shown in Table 1). Study enrollment is
shown in Figure 1, during the study, some patients
showed an increment of flatulence, diarrhea and meteor-
ism, without statistical significance.Treatment compliance
In all groups, we observed an adherence upper than
98%, with good tolerance and we did not identify serious
side effects that forced us to suspend the regimen.Table 1 Demographic and clinical baseline characteristics of a
Characteristics Probiotic n = 5






Body mass index (kg/m2) Mean ± SD 24 ± 2
Clinical stage (%) Stage A: 15
Stage B: 85
HIV RNA level (copies/mL), median 68100
CD4 cell count (cells/mm3), mean 754
Cholesterol (mg/dL) Mean ± SD 137 ± 16
Triglycerides (mg/dL) Mean ± SD 88 ± 27
IBS-QoL scale score 34Bacterial translocation and bacterial stool composition
A reduction in bacterial DNA concentrations in plasma
was observed in the probiotics, synbiotic, and prebiotic
groups, but statistical significance was reached only in the
synbiotic group (p = 0.048) (Figure 2). Additionally, the
probiotic and synbiotic groups demonstrated a decrease in
total bacterial load in feces (p = 0.045 and 0.048, respect-
ively). The prebiotic group showed a tendency toward
higher bacterial load in feces (data non shown). On the
other hand, some differences in bacterial stool compos-
ition were found between groups; the probiotic group
exhibited a significant increase of microbial load of Bifido-
bacterium spp. (p = 0.049) and a decrease in Clostridium
spp. (p = 0.063), while the synbiotic group demonstrated
a reduction non-significant in beneficial and harmful bac-
terial loads (p = 0.091 and p = 0.082, respectively) (Figure 3).
The prebiotic and placebo groups had similar behaviour
with an increased level of Bifidobacterium and Clostridium
load (not statistically significant) (data not shown).
Immunological parameters
Lymphocyte CD4+ T-cell count
At the end of the study, all patients under treatment
showed an increase of CD4+ T lymphocytes; however,
the synbiotic group had greater increases in CD4+ T-cell
count (mean, +102 cells; p = 0.05) (Figure 4). No patient
merited exclusion due to a low level CD4+ T-cell count
and to the need to initiate ARV therapy; no patient had
a diagnosis of opportunistic infections.
Measurement of cytokines
Similar levels of TNF-α, IL-1β, and IL-10 cytokines were
found in all groups during enrollment and at the end of
the study (data not shown). The IL-6 cytokine level
decreased significantly in the synbiotic group (p = 0.016)s-treated patients
Synbiotic n = 5 Prebiotic n = 5 Placebo n = 5
26 ± 7 27 ± 6 30 ± 8
5 4 5
0 1 0
5 (100) 5 (100) 5 (100)
23 ± 6 25 ± 6 24 ± 6
Stage A: 14 Stage A: 10 Stage A: 18
Stage B: 86 Stage B: 90 Stage B: 82
56881 40800 54460
620 533 542
161 ± 32 179 ± 53 148 ± 13
105 ± 27 149 ± 65 118 ± 79
36 35 34
Assessed for eligibility (n = 22)
Randomized (n = 20)
Excluded (n = 2)
- Did not meet eligibility criteria (1)














2 patients had diarrhea
Adverse events:
3 patients had flatulence
1 patient had diarrhea
Adverse events:
3 patients had flatulence
1 patient had meteorism
Adverse events:
2 patients had diarrhea
Figure 1 Study enrollment. Twenty-two patients were screening, two of them were excluded before the randomized visit, and the remainder
completed the 16 weeks of treatment.
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and CD4+ T-cells was revealed in the placebo group
(r = −0.99; p = 0.008) (Figure 6).
Discussion
Within the immunopathogenesis of HIV infection, there
is a state of constant systemic immune activation thatFigure 2 Microbial translocation. Quantification of bacterial 16 s rDNA e
differences found in the four study groups at enrollment and the end of th
the synbiotic group. Data shown in mean ± Standard error of the mean (SEis attributed in part to the enteropathy caused by
HIV itself and to the translocation of microbes and/or
microbial products from the intestinal lumen into the
circulation [8,30].
We evaluated the efficacy and safety of Lactobacillus
rhamnosus HN001 plus Bifidobacterium lactis Bi-07
at 109 cfu/mL as probiotics, 10 g of agave inulin asxtracted from plasma in the different groups. The graph shows the
e study, in which the only group to reach statistical significance was
M).
Figure 3 Bacterial composition in feces. Quantification of bacterial composition in feces in probiotic and synbiotic groups. The graph shows
the differences from baseline to week 16. The probiotic group demonstrated an increase in beneficial bacterial DNA levels achieving statistical
significance (*p = 0.049) and a tendency of decrease in harmful bacterial DNA levels (**p = 0.063). The synbiotic group had a tendency of decrease
both type of bacterias ***p = 0.082, ****p = 0.091. Data shown in mean.
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antiretroviral-naïve, HIV-infected subjects.
There have been some studies in patients with HIV
infection, using different probiotics in which mixed
results have been obtained; this is perhaps secondary
to the use of different concentrations and probiotic
strains, which do not trigger the same immunostimula-
tory effect [15,31,32].
Certain serious adverse effects have been reported with
the use of probiotics, particularly endocarditis, liver
abscess, bacteremia, and septicemia or septic shock,
especially in immunocompromised patients, or in patients
with chronic disease, or in those with ventilatory support
or with central venous catheters [33-35]. During the study,
we received no report of serious adverse events, no clinic-
ally significant changes were noted in any safety parameter
measured, and no patient developed sepsis, bacteremia,



























Figure 4 Quantification of CD4+ T cells. Quantification of CD4+
T cells in peripheral blood in all groups, before and after treatment.
The graph shows that the synbiotic group had a statistically
significant elevation in CD4+ T cell levels (median: +102 cells/μL).load in feces decreased in probiotics and synbiotic groups
and, the probiotics group showed an increase in the
concentration of beneficial bacteria, as Bifidobacterium
species, which have less potential for adhesion and trans-
location [12]. Further, we found that the synbiotic group
had a tendency of reduction in beneficial and harmful bac-
terial loads and had a significant reduction in the concen-
tration of bacterial translocation.
ARV treatment has increased survival in patients with
HIV infection; however, survival is at least 10 years lessFigure 5 Levels of Interleukin 6 (IL-6) in all groups.
Concentration of IL-6 in plasma at baseline and at week 16.
The decrease of IL-6 in synbiotic group was statistically significant
(p = 0.016), changes in the other groups were not significant.
Data shown in mean ± Standard error of the mean (SEM).





r  = 0.99
p = 0.008















Figure 6 Correlation between Interleukin 6 (IL-6) levels in
plasma and CD4+ T-cell count in peripheral blood. Using the
Spearman test, a negative correlation between IL-6 concentration
in plasma and absolute CD4+ T-cell number in peripheral blood
was demonstrated in the placebo group, with statistical significance
(r = −0.99; p = 0.008).
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risk is twice as high in HIV-positive subjects [36]. In our
study, the use of the synbiotic demonstrated a significant
decrease in the concentration of cytokine IL-6, which
has been utilized as a marker of cardiovascular risk,
accelerated atherosclerosis, and mortality in HIV-
infected patients [37]. However, it would therefore be
important to assess, in our study, other cardiovascular
risk-related parameters, such as D-dimer and high-
sensitivity C-reactive protein [38].
ARV drugs can cause several adverse effects including
dyslipidemia, insulin resistance, lactic acidosis, lipody-
strophy, and diarrhea, among others [39,40]. Our study
demonstrated a significant increase in CD4+ T lympho-
cyte levels in the synbiotic group, which could delay
time of initiation of ARV treatment and decrease costs
in countries with limited resources. Moreover, in our
region, the agave pines of Agave tequilana Weber var.
azul are widely employed to produce the national drink,
tequila, and could also be a potential source of prebiotics
and part of synbiotic with accessible prices.
On the other hand, we found no decrease in HIV-1
plasma viral load; therefore, the use of a synbiotic
could not provide the benefit of maintaining an
undetectable viral load as part of the primary prevention
of HIV transmission.
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